Treatment of Advanced-Stage Sertoli-Leydig Cell Tumor (SLCT): A Clinicopathologic Study of 1 Case.
- Author:
Jung Shick KIM
1
;
Young Min YOON
;
Chong Woo YOO
;
Hyun A JUN
;
Hong Bae KIM
;
Guen Young LEE
;
Sung Won KANG
Author Information
1. Department of Obstetrics and Gynecology, KangNam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Sertoli-Leydig Cell Tumor
- MeSH:
Drug Therapy;
Fatal Outcome;
Female;
Humans;
Hysterectomy;
Lymph Node Excision;
Menopause;
Middle Aged;
Ovary;
Prognosis;
Recurrence;
Sertoli-Leydig Cell Tumor*;
Survival Rate;
Testosterone;
Uterine Hemorrhage
- From:Korean Journal of Obstetrics and Gynecology
2002;45(11):2057-2061
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sertoli-Leydig cell tumors belong to the group of sex-cord stromal tumors of the ovary. They account for less than 0.5% of all ovarian tumor. They occur predominantly at premenopausal women and rarely at postmenopausal and prepubertal. Most common symptom is menstrual disorder including vaginal bleeding. This symptom is the results of excessive testosterone production of Leydig cell. Masculinization is occasionally accompanied by this symptom. but approximately 50% of patients with SLCT have no endocrine manifestations. Prognosis prove generally favorable with 5-year survival rate of 70-90%. Recurrence is rare.The majority of these tumors are benign and are unilaterally (97-98%) localized. Surgery varies with patient age, tumor stage, and differentiation from unilateral salpingo-oophorectomy to bilateral salpingo-oophorectomy and total hysterectomy concomitant with pelvic lymph node dissection. Herewith, we experienced a case of treatment advanced-stage Sertoli-Leydig cell tumor with poorly differentiation in that is ascitic and metastatic in a 53 years old menopause woman who has no virilizing symptom. After all the tumor has resulted in fatal outcome despite of surgery and aggressive chemotherapy. Therefore we present it with review of literature.
